Torrent Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Torrent Pharmaceuticals Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 3464, up 2.43% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.98% on the day, quoting at 23962.25. The Sensex is at 79274.83, down 1.13%. Torrent Pharmaceuticals Ltd has risen around 11.67% in last one month.

Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has risen around 3.99% in last one month and is currently quoting at 22314.55, up 1.32% on the day. The volume in the stock stood at 3.15 lakh shares today, compared to the daily average of 3.56 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 3468.45, up 2.22% on the day. Torrent Pharmaceuticals Ltd is up 61.34% in last one year as compared to a 13.3% spurt in NIFTY and a 40.24% spurt in the Nifty Pharma index.

The PE of the stock is 69.93 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

The brands include Cospiaq (empagliflozin), Cospiaq Met (empagliflozin + metformin) and Xilingio (empagliflozin + linagliptin), which are used in the treatment of type 2 diabetes.

Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor which is indicated for glycemic control in adults with type 2 diabetes mellitus. The market for SGLT-2 inhibitors is valued at Rs 3,235 crore and the SGLT-2 inhibitors are growing faster than the diabetes market at 25% CAGR.

As per the International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (20-79 years age group) as of 2021. This is expected to increase to almost 125 million patients by 2045. According to AWACS MAT October 2024 data, the Indian diabetes medications market is valued at Rs 19,912 crore, growing at 7.7% CAGR over the last 4 years.

The acquisition is expected to be completed in March 2025. The company has been marketing these brands since 2022 as part of an existing co-marketing agreement with Boehringer Ingelheim India.

Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology.

The company’s consolidated net profit increased 17.35% to Rs 453 crore on 8.6% rise in revenue from operations to Rs 2,889 crore in Q2 FY25 over Q2 FY24.

The scrip shed 0.31% to Rs 3,339.25 on the BSE.

Powered by Capital Market - Live News

Torrent Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 3387.2, up 1.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Torrent Pharmaceuticals Ltd has added around 5.83% in last one month.

Meanwhile, Nifty Pharma index of which Torrent Pharmaceuticals Ltd is a constituent, has added around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 2.69 lakh shares today, compared to the daily average of 3.54 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 3392.4, up 1.23% on the day. Torrent Pharmaceuticals Ltd is up 58.76% in last one year as compared to a 18.09% gain in NIFTY and a 38.64% gain in the Nifty Pharma index.

The PE of the stock is 69.06 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

“Based on the company assessment, the company will pursue an appeal and is hopeful of favorable outcome at higher forum and does not expect the said Order to have any material financial impact on the company,” it added.

Torrent Pharmaceuticals is the flagship company of the Torrent Group. It is ranked 6th in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of cardiovascular (CV), gastro intestinal (GI), central nervous system (CNS), vitamins minerals nutritional (VMN) and cosmo-dermatology.

The company’s consolidated net profit increased 17.35% to Rs 453 crore on 8.6% rise in revenue from operations to Rs 2,889 crore in Q2 FY25 over Q2 FY24.

Shares of Torrent Pharmaceuticals rallied 3.11% to currently trade at Rs 3,303.40 on the BSE.

Powered by Capital Market - Live News